- Home
- PGEN vs RMM Comparison
PGEN vs RMM Comparison
Compare PGEN & RMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PGEN | RMM |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | 47 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 283.7M |
| IPO Year | 2013 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PGEN | RMM |
|---|---|---|
| Price | $7.77 | $12.72 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $8.33 | N/A |
| AVG Volume (30 Days) | ★ 3.7M | 57.0K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $230,981,000.00 | N/A |
| Revenue This Year | $1,115.92 | N/A |
| Revenue Next Year | $81.04 | N/A |
| P/E Ratio | $256.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.99 | $12.85 |
| 52 Week High | $8.04 | $15.00 |
Technical Indicators
Market Signals| Indicator | PGEN | RMM |
|---|---|---|
| Relative Strength Index (RSI) | 62.19 | 12.71 |
| Support Level | $6.57 | N/A |
| Resistance Level | N/A | $14.65 |
| Average True Range (ATR) | 0.38 | 0.20 |
| MACD | 0.03 | -0.08 |
| Stochastic Oscillator | 73.12 | 0.35 |
Price Performance
Historical ComparisonAbout PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
About RMM RiverNorth Managed Duration Municipal Income Fund Inc.
RiverNorth Managed Duration Muni Inc Fd is a United States based diversified, closed-end management investment company. Its primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.